Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional

Gemcitabine and ISIS 2503 in Treating Patients With Advanced or Metastatic Cancer of the Pancreas

ClinicalTrials.gov ID: NCT00006467

Public ClinicalTrials.gov record NCT00006467. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 11, 2026, 12:13 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase II Trial of Gemcitabine and ISIS 2503 in Patients With Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining gemcitabine with ISIS 2503 in treating patients who have advanced or metastatic cancer of the pancreas.

Study identification

NCT ID
NCT00006467
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Enrollment
48 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jan 31, 2001
Primary completion
Dec 31, 2003
Completion
Dec 31, 2003
Last update posted
Jul 5, 2016

2001 – 2004

United States locations

U.S. sites
16
U.S. states
10
U.S. cities
16
Facility City State ZIP Site status
CCOP - Scottsdale Oncology Program Scottsdale Arizona 85259-5404
CCOP - Carle Cancer Center Urbana Illinois 61801
CCOP - Cedar Rapids Oncology Project Cedar Rapids Iowa 52403-1206
CCOP - Iowa Oncology Research Association Des Moines Iowa 50309-1016
Siouxland Hematology-Oncology Sioux City Iowa 51101-1733
CCOP - Wichita Wichita Kansas 67214-3882
CCOP - Duluth Duluth Minnesota 55805
Mayo Clinic Cancer Center Rochester Minnesota 55905
CentraCare Clinic Saint Cloud Minnesota 56303
CCOP - Missouri Valley Cancer Consortium Omaha Nebraska 68131
Medcenter One Health System Bismarck North Dakota 58501
CCOP - Merit Care Hospital Fargo North Dakota 58122
CCOP - Toledo Community Hospital Oncology Program Toledo Ohio 43623-3456
CCOP - Geisinger Clinic and Medical Center Danville Pennsylvania 17822-2001
Rapid City Regional Hospital Rapid City South Dakota 57709
CCOP - Sioux Community Cancer Consortium Sioux Falls South Dakota 57105-1080

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT00006467, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 5, 2016 · Synced Sep 11, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT00006467 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →